Pasithea Therapeutics Corp Stock Performance
| KTTA Stock | USD 0.71 0 0.68% |
Pasithea Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The company holds a Beta of 2.79, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pasithea Therapeutics will likely underperform. Use Pasithea Therapeutics value at risk and the relationship between the expected short fall and market facilitation index , to analyze future returns on Pasithea Therapeutics.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Pasithea Therapeutics Corp are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Pasithea Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:20 | Last Split Date 2024-01-02 |
1 | Acquisition by Steinman Lawrence of 242913 shares of Pasithea Therapeutics at 0.715 subject to Rule 16b-3 | 11/21/2025 |
2 | Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic , ... | 11/24/2025 |
3 | Insiders Buying Pasithea Therapeutics Might Wish They Invested More, Stock Gains 10 | 12/04/2025 |
4 | Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com Nigeria | 12/08/2025 |
5 | Acquisition by Daniel Schneiderman of 300000 shares of Pasithea Therapeutics subject to Rule 16b-3 | 12/12/2025 |
6 | What hedge fund activity signals for Pasithea Therapeutics Corp. Equity Warrant stock - Long Setup Accurate Entry and Exit Point Alerts - | 12/18/2025 |
7 | Acquisition by Shahinian Eric of 21748 shares of Pasithea Therapeutics at 1.1326 subject to Rule 16b-3 | 01/02/2026 |
8 | Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines | 01/13/2026 |
9 | Short Interest in Pasithea Therapeutics Corp. Increases By 23.8 | 01/20/2026 |
10 | Can Pasithea Therapeutics Corp. disrupt its industry - July 2025 Movers Consistent Return Strategy Ideas - mfd.ru | 02/12/2026 |
Pasithea Therapeutics Relative Risk vs. Return Landscape
If you would invest 48.00 in Pasithea Therapeutics Corp on November 19, 2025 and sell it today you would earn a total of 23.00 from holding Pasithea Therapeutics Corp or generate 47.92% return on investment over 90 days. Pasithea Therapeutics Corp is currently generating 1.7885% in daily expected returns and assumes 18.2502% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Pasithea, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pasithea Therapeutics Target Price Odds to finish over Current Price
The tendency of Pasithea Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.71 | 90 days | 0.71 | about 83.06 |
Based on a normal probability distribution, the odds of Pasithea Therapeutics to move above the current price in 90 days from now is about 83.06 (This Pasithea Therapeutics Corp probability density function shows the probability of Pasithea Stock to fall within a particular range of prices over 90 days) .
Pasithea Therapeutics Price Density |
| Price |
Predictive Modules for Pasithea Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pasithea Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Pasithea Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Pasithea Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pasithea Therapeutics is not an exception. The market had few large corrections towards the Pasithea Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pasithea Therapeutics Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pasithea Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.89 | |
β | Beta against Dow Jones | 2.79 | |
σ | Overall volatility | 0.23 | |
Ir | Information ratio | 0.06 |
Pasithea Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pasithea Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pasithea Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pasithea Therapeutics is way too risky over 90 days horizon | |
| Pasithea Therapeutics has some characteristics of a very speculative penny stock | |
| Pasithea Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (13.9 M) with loss before overhead, payroll, taxes, and interest of (2.21 K). | |
| Pasithea Therapeutics Corp currently holds about 47.94 M in cash with (13.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pasithea Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Can Pasithea Therapeutics Corp. disrupt its industry - July 2025 Movers Consistent Return Strategy Ideas - mfd.ru |
Pasithea Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Pasithea Stock often depends not only on the future outlook of the current and potential Pasithea Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pasithea Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.1 M | |
| Cash And Short Term Investments | 6.9 M |
Pasithea Therapeutics Fundamentals Growth
Pasithea Stock prices reflect investors' perceptions of the future prospects and financial health of Pasithea Therapeutics, and Pasithea Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pasithea Stock performance.
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 4.43 M | ||||
| Shares Outstanding | 22.4 M | ||||
| Price To Book | 1.34 X | ||||
| Price To Sales | 42.15 X | ||||
| Gross Profit | (2.21 K) | ||||
| EBITDA | (13.6 M) | ||||
| Net Income | (13.9 M) | ||||
| Cash And Equivalents | 47.94 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 1.28 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 51.17 X | ||||
| Book Value Per Share | 1.64 X | ||||
| Cash Flow From Operations | (13.92 M) | ||||
| Earnings Per Share | (4.43) X | ||||
| Market Capitalization | 25.09 M | ||||
| Total Asset | 16.06 M | ||||
| Retained Earnings | (49.58 M) | ||||
| Working Capital | 6.25 M | ||||
About Pasithea Therapeutics Performance
By analyzing Pasithea Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Pasithea Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pasithea Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pasithea Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.13) | (2.03) | |
| Return On Capital Employed | (1.10) | (1.04) | |
| Return On Assets | (1.00) | (0.95) | |
| Return On Equity | (1.08) | (1.03) |
Things to note about Pasithea Therapeutics performance evaluation
Checking the ongoing alerts about Pasithea Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pasithea Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pasithea Therapeutics is way too risky over 90 days horizon | |
| Pasithea Therapeutics has some characteristics of a very speculative penny stock | |
| Pasithea Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (13.9 M) with loss before overhead, payroll, taxes, and interest of (2.21 K). | |
| Pasithea Therapeutics Corp currently holds about 47.94 M in cash with (13.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pasithea Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Can Pasithea Therapeutics Corp. disrupt its industry - July 2025 Movers Consistent Return Strategy Ideas - mfd.ru |
- Analyzing Pasithea Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pasithea Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Pasithea Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pasithea Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pasithea Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pasithea Therapeutics' stock. These opinions can provide insight into Pasithea Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pasithea Stock analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |